CA2602254C — Rho kinase inhibitors
Assigned to Surface Logix Inc · Expires 2015-03-24 · 11y expired
What this patent protects
The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. In one aspect, the invention relates to a compound of formula (I): (see formula ) or to a pharmaceutically acceptable…
USPTO Abstract
The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. In one aspect, the invention relates to a compound of formula (I): (see formula ) or to a pharmaceutically acceptable salt or hydrate thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.